• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[格雷夫斯病发病机制与诊断的最新进展]

[The latest progress in the pathogenesis and diagnosis of Graves' disease].

作者信息

Kimura Tetsuya, Okamoto Yasuyuki

机构信息

Department of Immunopathology, WPI Immunology Frontier Research Center, Osaka University.

出版信息

Nihon Rinsho. 2012 Nov;70(11):1908-12.

PMID:23214060
Abstract

Graves' disease is a unique autoimmune disease with cell proliferation and excess function, caused by anti-thyrotropin receptor antibody (TRAb), and apart from antibody-mediated organ destruction seen in other autoimmune diseases. In this article, we discuss the latest progress in the research field of TRAb. The biological natures of various TRAbs are also summarized. Additionally, we introduce the development of a full-automated and rapid measurement system for TRAb. Measurement of the titer of TRAb within one hour in office setting enables clinicians to make more concrete diagnosis of Graves' disease at the first visit of patients.

摘要

格雷夫斯病是一种独特的自身免疫性疾病,具有细胞增殖和功能亢进的特点,由抗促甲状腺素受体抗体(TRAb)引起,与其他自身免疫性疾病中所见的抗体介导的器官破坏不同。在本文中,我们讨论了TRAb研究领域的最新进展。还总结了各种TRAb的生物学特性。此外,我们介绍了一种用于TRAb的全自动快速测量系统的开发。在门诊环境中一小时内测量TRAb滴度,使临床医生能够在患者首次就诊时对格雷夫斯病做出更确切的诊断。

相似文献

1
[The latest progress in the pathogenesis and diagnosis of Graves' disease].[格雷夫斯病发病机制与诊断的最新进展]
Nihon Rinsho. 2012 Nov;70(11):1908-12.
2
Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.在格雷夫斯病中,参照甲状腺刺激抗体和甲状腺刺激阻断抗体,对促甲状腺素受体抗体新的不同检测系统进行比较。
Int J Clin Pharmacol Res. 2004;24(4):111-6.
3
Clinical review about TRAb assay's history.TRAb 检测的历史临床评估。
Autoimmun Rev. 2010 Aug;9(10):695-700. doi: 10.1016/j.autrev.2010.05.021. Epub 2010 Jun 4.
4
Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.与促甲状腺素受体结合、刺激及阻断的促甲状腺素受体抗体作为抗甲状腺治疗停药后Graves病复发的预测指标
Horm Metab Res. 2005 Dec;37(12):745-50. doi: 10.1055/s-2005-921102.
5
Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.新型嵌合促甲状腺激素受体生物测定法与自动化促甲状腺激素受体结合测定法在 Graves 病中的临床性能相似。
Thyroid. 2011 Dec;21(12):1295-9. doi: 10.1089/thy.2011.0056. Epub 2011 Nov 8.
6
The role of TSH receptor antibodies in the management of Graves' disease.促甲状腺素受体抗体在 Graves 病治疗中的作用。
Eur J Intern Med. 2011 Jun;22(3):213-6. doi: 10.1016/j.ejim.2011.02.006. Epub 2011 Mar 22.
7
Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.阿曼格雷夫斯病患者甲状腺刺激激素受体抗体与甲状腺过氧化物酶抗体水平的测定。
Med Princ Pract. 2005 Jul-Aug;14(4):209-12. doi: 10.1159/000085736.
8
Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).第二代抗促甲状腺素受体抗体(TRAb)放射免疫分析法在自身免疫性甲状腺疾病中的评估。与第一代抗促甲状腺素受体抗体及抗甲状腺过氧化物酶抗体(AbTPO)的比较。
Q J Nucl Med. 2001 Mar;45(1):115-9.
9
Identification and functionalization of thyrotropin receptor antibodies with different antigenic epitopes.鉴定和功能化具有不同抗原表位的促甲状腺激素受体抗体。
Am J Physiol Endocrinol Metab. 2024 Sep 1;327(3):E328-E343. doi: 10.1152/ajpendo.00123.2024. Epub 2024 Jul 24.
10
The negative correlation between thyrotropin receptor-stimulating antibodies and bone mineral density in postmenopausal patients with Graves' disease.促甲状腺素受体刺激抗体与绝经后 Graves 病患者骨密度的负相关关系。
J Investig Med. 2013 Jun;61(5):842-7. doi: 10.2310/JIM.0b013e31828fcafb.